格卡瑞韦/哌仑他韦在慢性丙型肝炎1-6型合并代偿性肝病患者中的安全性与药代动力学
该整合分析纳入9项II/III期临床试验的2369例慢性HCV 1-6型感染且伴代偿性肝病患者,评估G/P治疗8-16周的安全性与疗效。结果显示总体安全性良好,代偿性肝硬化患者SVR12为96.4%,无肝硬化患者为97.5%;肝硬化患者格卡瑞韦暴露增加2.2倍,但哌仑他韦暴露未增加。
要点
- G/P在代偿性肝病(含CKD 4/5)患者中安全有效,SVR12高。
- 代偿性肝硬化患者格卡瑞韦暴露增加2.2倍,但未见药物性肝损伤或临床相关肝功能失代偿。
- 因不良事件停药或G/P相关严重不良事件发生率<1%。
核心结论
- G/P在代偿性肝病(包括CKD 4/5)的慢性HCV 1-6型感染患者中安全且有效。
研究设计与样本
- 整合9项II期和III期临床试验,评估G/P治疗8-16周的安全性与疗效,共纳入2369例患者。
- 肝硬化通过肝活检、瞬时弹性成像或血清生物标志物在筛查时确定。
主要发现
- 2369例患者中308例(13%)为Child-Pugh A级,其中20例为CKD 4/5。
- 因不良事件导致G/P停药或G/P相关严重不良事件的发生率<1%。
- 最常见不良事件为头痛和乏力,伴或不伴肝硬化者发生率相似。
- 严重不良事件在CKD 4/5患者中更常见,但均与G/P无关。
- 无药物性肝损伤或临床相关肝功能失代偿病例。
临床怎么用
- G/P可用于慢性HCV 1-6型感染合并代偿性肝病(包括CKD 4/5)患者的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). METHODS: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver biopsy, transient elastography, or serum biomarkers. The objectives were to evaluate safety, the rate of sustained virologic response at post-treatment week 12 (SVR12), and steady-state PK by cirrhosis status. RESULTS: Among 2369 patients, 308 (13%) were Child-Pugh Class A, including 20 with CKD 4/5. Overall, <1% of patients experienced an adverse event (AE) that led to G/P discontinuation or G/P-related serious AEs (SAEs). The most common AEs were headache and fatigue, occurring at similar frequencies with and without cirrhosis. SAEs were more common in patients with CKD 4/5, but all were unrelated to G/P. There were no cases of drug-induced liver injury or clinically relevant hepatic decompensation. SVR12 rates were 96.4% (297/308) with compensated cirrhosis and 97.5% (2010/2061) without cirrhosis. PK analysis demonstrated a 2.2-fold increase in glecaprevir exposure, but not pibrentasvir exposure, in patients with compensated cirrhosis. CONCLUSIONS: G/P was safe and efficacious in patients with compensated liver disease, including those with CKD 4/5. CLINICAL TRIALS REGISTRATION: NCT02243280, NCT02243293, NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, and NCT02446717.
引用
- Gane E, Poordad F, Zadeikis N, et al. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis. 2019. PMID: 30923816. doi:10.1093/cid/ciz022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。